AstraZeneca, GSK intensify China ties with Sino Biopharm deals
AstraZeneca, GSK intensify China ties with Sino Biopharm deals
Sino Biopharmaceutical
HKEX: 1177 ~$10B MCAP
Hong Kong-listed (HKEX: 1177) pharmaceutical conglomerate specializing in biopharmaceuticals, modern Chinese medicine, and chemical medicines. Therapeutic focus on hepatobiliary, oncology, cardiovascular, and respiratory diseases.
Company Info
Upcoming Milestones & Key Dates
2026-Q3
business
AstraZeneca $1.9B respiratory collaboration expected to close
2026-Q4
business
GSK respiratory alliance close
Clinical Development Pipeline
TQB2450
Target: PD-L1Furmonertinib
Target: EGFR-T790MTQB3616
Target: RSV fusion inhibitorRecent News
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical (reported by BioSpace)
Leadership Team
Tse Ping
Chairman and Chief Executive Officer
Theresa Cheung
Executive Director
Careers & Job Openings